Solventum (MEX:SOLV) Change In Receivables : MXN5,097 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Solventum Change In Receivables?

Solventum's change in receivables for the quarter that ended in Dec. 2024 was MXN1,293 Mil. It means Solventum's Accounts Receivable declined by MXN1,293 Mil from Sep. 2024 to Dec. 2024 .

Solventum's change in receivables for the fiscal year that ended in Dec. 2024 was MXN5,756 Mil. It means Solventum's Accounts Receivable declined by MXN5,756 Mil from Dec. 2023 to Dec. 2024 .

Solventum's Accounts Receivable for the quarter that ended in Dec. 2024 was MXN21,773 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Solventum's Days Sales Outstanding for the three months ended in Dec. 2024 was 45.91.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Solventum's liquidation value for the three months ended in Dec. 2024 was MXN-197,514 Mil.

Solventum Change In Receivables Historical Data

The historical data trend for Solventum's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solventum Change In Receivables Chart

Solventum Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

815.57

-20.51

-623.87

-2,189.68

5,756.17

Solventum Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial						-1,782.30	1,294.51	2,253.37	255.97	1,293.05

Solventum Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN5,097 Mil.

Solventum (MEX:SOLV) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Solventum's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	21773.351	/	43275.577	*	91
=	45.91

2. In Ben Graham's calculation of liquidation value, Solventum's accounts receivable are only considered to be worth 75% of book value:

Solventum's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	15892.043	-	239798.838	+	0.75 * 21773.351	+	0.5 * 20125.75
=	-197,514

Solventum Change In Receivables Related Terms

Thank you for viewing the detailed overview of Solventum's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Solventum Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Solventum Corp (MEX:SOLV) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

SOLV:USA KB7:Germany

Address

2510 Conway Avenue East, 3M Center, Building 275-6W, Maplewood, MN, USA, 55144

Website

https://www.solventum.com/en-us/home

Solventum Corp is a healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer and patient needs. The company has four operating segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company generates the majority of its revenue from the MedSurg segment, which provides wound care and surgical solutions that are intended to accelerate healing, prevent complications, and lower the total cost of care globally.